Vidarabine Monohydrate: Antiviral Nucleoside Analog for DNA Replication Interference

Executive Summary: Vidarabine monohydrate (also known as Spongoadenosine monohydrate or Vira-A monohydrate) is a nucleoside analog with the molecular formula C₁₀H₁₅N₅O₅·H₂O, primarily used as an antiviral research compound. It inhibits viral DNA synthesis by mimicking adenosine nucleosides, interfering with DNA replication in viruses such as herpes simplex virus (HSV) [APExBIO]. Vidarabine monohydrate is insoluble in water and ethanol but highly soluble in DMSO (≥49.4 mg/mL), supporting its use in biochemical assays. The compound is provided at ≥98% purity and must be stored at -20°C for stability. These properties make it a critical tool in translational virology and antiviral drug discovery [A40926Source].

Biological Rationale

Vidarabine monohydrate is a synthetic nucleoside analog designed to mimic naturally occurring adenosine. By doing so, it becomes incorporated into viral DNA during replication cycles. This incorporation disrupts normal polymerization and leads to premature chain termination [APExBIO]. The compound's primary research application is the study of DNA viruses, including herpes simplex virus (HSV) and varicella-zoster virus (VZV), both of which rely on robust DNA synthesis for propagation [DNA Remover]. Vidarabine monohydrate's structure—(2R,3S,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol hydrate—confers selectivity for viral DNA polymerases over host enzymes, reducing off-target effects in in vitro systems.

Mechanism of Action of Vidarabine monohydrate

Vidarabine monohydrate acts as an adenosine analog. Upon entering infected cells, it is phosphorylated to vidarabine triphosphate by cellular kinases. This active triphosphate form competes with deoxyadenosine triphosphate (dATP) for incorporation by viral DNA polymerases [HOBT-Anhydrous]. Once incorporated, it disrupts the formation of phosphodiester bonds, leading to chain termination and inhibition of further DNA elongation. This blockage is most pronounced in herpesviridae family members, where DNA-dependent DNA polymerases have high affinity for nucleoside analogs. Vidarabine monohydrate shows negligible activity against RNA viruses, as their replication machinery does not utilize DNA intermediates [RT-Supermix]. The molecular interference provided by this compound allows researchers to dissect viral replication kinetics and test combination strategies with other antiviral agents.

Evidence & Benchmarks

• Vidarabine monohydrate achieves ≥49.4 mg/mL solubility in DMSO, enabling preparation of high-concentration stock solutions for in vitro assays (APExBIO).
• The compound demonstrates ≥98% purity as validated by HPLC analysis, supporting reproducible experimental results (APExBIO).
• Vidarabine triphosphate selectively inhibits viral DNA polymerase activity without significant inhibition of host cellular DNA polymerase at standard research concentrations (10–100 μM) (DNA Remover).
• In herpes simplex virus research models, Vidarabine monohydrate effectively reduces viral DNA synthesis, as measured by qPCR and plaque assays at 37°C in standard cell culture buffers (A40926Source).
• Stability data indicate that Vidarabine monohydrate retains ≥95% integrity when stored at -20°C for up to 12 months, but solutions in DMSO should be used within days to prevent hydrolysis (APExBIO).

Applications, Limits & Misconceptions

Vidarabine monohydrate is widely used to study antiviral mechanisms, screen for resistance mutations, and as a benchmark in the development of new nucleoside analogs. Its high DMSO solubility allows for flexible dosing and rapid assay development. APExBIO provides the C6377 kit specifically for research use, not for clinical or diagnostic applications.

This article extends previous mechanistic reviews by providing updated stability and solubility data, and clarifies workflow integration strategies for translational virology models.

Common Pitfalls or Misconceptions

• Vidarabine monohydrate is not effective against RNA viruses, as its mechanism targets DNA polymerases.
• Long-term storage of solutions (even in DMSO) leads to hydrolysis; freshly prepared stocks are recommended.
• Clinical use is not permitted; this product is intended for laboratory research only.
• Its selectivity for viral over host DNA polymerase is high but not absolute—high concentrations may still affect host cells.
• Solubility is low in water and ethanol; DMSO is required for effective dissolution.

Workflow Integration & Parameters

For optimal results, Vidarabine monohydrate should be dissolved in DMSO at concentrations up to 49.4 mg/mL. Stock solutions should be aliquoted and stored at -20°C, avoiding repeated freeze-thaw cycles. For in vitro assays, typical working concentrations range from 1 to 100 μM, depending on the viral system and endpoint readout. Researchers should verify solubility at their working temperature and buffer conditions. Controls using DMSO alone should be included to account for solvent effects. The high purity of the C6377 kit from APExBIO enables reproducible results across different labs [product page].

Compared to prior summaries such as RT-Supermix, which focused on mechanism, this guide details precise handling and integration for advanced assay development.

Conclusion & Outlook

Vidarabine monohydrate remains a cornerstone antiviral nucleoside analog for DNA replication interference in viral research. Its high solubility in DMSO, robust storage stability, and selectivity for viral DNA polymerases make it indispensable for herpes simplex virus and related model systems. Ongoing research continues to refine its applications, including combination therapies and resistance profiling. APExBIO's commitment to high-purity, well-characterized reagents supports innovation in antiviral discovery. For further reading on novel assay integration and mechanistic insight, see DNA Remover, which this article updates by clarifying storage and solubility guidance for reproducible workflows.